Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.

Van Kampen SC, Tursynbayeva A, Koptleuova A, Murzabekova Z, Bigalieva L0, Aubakirova M, Pak S, van den Hof S.

PLoS One. 2015;10(7):e0132514.

Abstract  http://www.ncbi.nlm.nih.gov/pubmed/?term=Effect+of+Introducing+Xpert+MTB%2FRIF+to+Test+and+Treat+Individuals+at+Risk+of+Multidrug-Resistant+Tuberculosis+in+Kazakhstan%3A+A+Prospective+Cohort+Study

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us